MRX 6 / Akari Therap - LARVOL DELTA

Mrx6 binds the Lon protease Pim1 N-terminal domain to confer selective substrate specificity and regulate mtDNA copy number. (PubMed, Nucleic Acids Res) - "Additionally, Mrx6 loss alters Cim1's function, preventing the detrimental effect on mtDNA maintenance observed upon Cim1 overexpression. The presence of three Pet20-domain proteins in yeast implies broader roles of Lon protease substrate recognition beyond mtDNA regulation."

Journal • PIM1

C012013: Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (clinicaltrials.gov) - P2; N=73; Terminated; Sponsor: Celsus Therapeutics PLC; Recruiting ➔ Terminated; Trial primary completion date: Dec 2014 ➔ Mar 2015

Trial primary completion date • Trial termination • Biosimilar • Dermatitis • Eczema • Immunology

Mrx6 regulates mitochondrial DNA copy number in S. cerevisiae by engaging the evolutionarily conserved Lon protease Pim1. (PubMed, Mol Biol Cell) - "No further increase of mtDNA copy number was observed upon depletion of Pim1 in Δmrx6 cells, revealing an epistatic relationship between Pim1 and Mrx6. Human and bacterial Lon proteases regulate DNA replication by degrading replication initiation factors, suggesting a model in which Pim1 acts similarly with the Mrx6 complex providing a scaffold linking it to mtDNA."

Journal